Wall Street analysts predict that Sharps Compliance Corp. (NASDAQ:SMED) will post $15.11 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Sharps Compliance’s earnings. The lowest sales estimate is $14.74 million and the highest is $15.80 million. Sharps Compliance posted sales of $13.60 million during the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The company is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, October 27th.

On average, analysts expect that Sharps Compliance will report full year sales of $58.18 million for the current year, with estimates ranging from $57.43 million to $58.60 million. For the next financial year, analysts expect that the business will post sales of $63.15 million, with estimates ranging from $61.05 million to $65.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Sharps Compliance.

Sharps Compliance (NASDAQ:SMED) last released its earnings results on Wednesday, August 19th. The industrial products company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.12. Sharps Compliance had a return on equity of 8.11% and a net margin of 4.43%. The business had revenue of $12.57 million for the quarter, compared to the consensus estimate of $12.83 million. During the same quarter in the previous year, the business earned $0.03 earnings per share.

A number of research firms have recently commented on SMED. Lake Street Capital started coverage on shares of Sharps Compliance in a report on Wednesday, July 15th. They issued a “buy” rating and a $10.00 target price for the company. Barrington Research reiterated a “buy” rating and issued a $9.00 price target on shares of Sharps Compliance in a research report on Friday, August 21st. TheStreet raised Sharps Compliance from a “c” rating to a “b” rating in a research note on Friday, August 21st. Finally, Zacks Investment Research raised Sharps Compliance from a “sell” rating to a “hold” rating in a research note on Thursday, August 27th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $8.25.

NASDAQ:SMED opened at $6.25 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.41 and a current ratio of 1.83. Sharps Compliance has a 52 week low of $3.74 and a 52 week high of $8.99. The firm’s 50-day simple moving average is $6.99 and its 200 day simple moving average is $7.10. The firm has a market cap of $102.64 million, a price-to-earnings ratio of 48.08, a P/E/G ratio of 2.89 and a beta of -0.61.

In other Sharps Compliance news, Director John W. Dalton sold 18,848 shares of Sharps Compliance stock in a transaction on Friday, August 21st. The shares were sold at an average price of $7.74, for a total value of $145,883.52. Following the completion of the sale, the director now directly owns 1,013,752 shares of the company’s stock, valued at $7,846,440.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John W. Dalton sold 19,492 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $7.71, for a total transaction of $150,283.32. Following the transaction, the director now owns 1,013,752 shares in the company, valued at approximately $7,816,027.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 122,699 shares of company stock worth $928,960. Insiders own 16.50% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its stake in Sharps Compliance by 178.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,107 shares of the industrial products company’s stock valued at $261,000 after purchasing an additional 23,785 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in shares of Sharps Compliance during the second quarter valued at about $1,500,000. Jane Street Group LLC acquired a new position in shares of Sharps Compliance during the second quarter valued at about $151,000. Mackay Shields LLC bought a new stake in shares of Sharps Compliance during the second quarter worth about $249,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sharps Compliance in the 2nd quarter worth about $94,000. Institutional investors and hedge funds own 43.59% of the company’s stock.

Sharps Compliance Company Profile

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste and used healthcare materials generated outside the hospital and health care facility settings; TakeAway Medication Recovery System, a solution that facilitates the proper disposal of unused medications; MedSafe, a solution for the safe collection, transportation, and proper disposal of unwanted and expired prescription medications; and ComplianceTRAC, a Web-based compliance and training program.

Read More: Why are trading ranges significant?

Get a free copy of the Zacks research report on Sharps Compliance (SMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sharps Compliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sharps Compliance and related companies with MarketBeat.com's FREE daily email newsletter.